Using active tumor targeting of a nanoformulation of echinomycin, our results indicate that SDC1-Lip echinomycin resulted in increased survival compared to echinomycin alone or Gemzar in orthotopic mouse models known to result in metastases. This evidence concerns the gene SDC1 and neoplasm.